TY - JOUR
T1 - Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification
T2 - Subanalysis of a prospective multicenter study
AU - Miki, Takashi
AU - Miyoshi, Toru
AU - Kotani, Kazuhiko
AU - Kohno, Kunihisa
AU - Asonuma, Hirohiko
AU - Sakuragi, Satoru
AU - Koyama, Yasushi
AU - Nakamura, Kazufumi
AU - Ito, Hiroshi
N1 - Funding Information:
This study was funded by the Japan Heart Foundation (No. 12090021 ).
Funding Information:
This study was funded by the Japan Heart Foundation (No. 12090021).
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/4
Y1 - 2019/4
N2 - Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95% confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.
AB - Background and aims: Oxidized high-density lipoprotein (oxHDL) is characterized by reduced anti-inflammatory properties compared with HDL. However, the role of oxHDL in the pathogenesis of coronary artery calcification (CAC), a marker of subclinical atherosclerosis, remains unclear. We prospectively investigated the association between the change in oxHDL and progression of CAC in a substudy of a multicenter study. Methods: In the principal study, patients with a CAC score of 1–999 were treated with pitavastatin with/without eicosapentaenoic acid. Measurement of CAC with multidetector-row computed tomography and a blood test were performed at baseline and at the 1-year follow-up. In the principal study, the increase in CAC did not differ among treatment groups. In this substudy, patients were divided into two groups: CAC progression (change in Agatston score of >0) and no CAC progression. Results: In total, 140 patients were analyzed. The oxHDL level significantly decreased from 167 (132–246) at baseline to 122 (103–149) after treatment (median [25 th –75th percentile], U/ml) (p < 0.001). The annual change in CAC was significantly positively associated with changes in oxHDL (r = 0.17, p = 0.04), triglycerides (r = 0.17, p = 0.04), and high-sensitivity C-reactive protein (r = 0.22, p = 0.01) but was not associated with changes in low-density lipoprotein cholesterol or HDL-cholesterol. Multiple logistic analysis demonstrated that the decrease in oxHDL per 10 U/ml was independently associated with CAC progression (odds ratio, 0.95; 95% confidence interval, 0.90–0.99; p = 0.04). Conclusions: The decrease in oxHDL is associated with the attenuation of CAC progression, suggesting that oxHDL is a potential target for atherosclerosis prevention.
KW - Atherosclerosis
KW - Computed tomography
KW - Coronary artery calcification
KW - High-density lipoprotein
KW - Oxidized lipoprotein
UR - http://www.scopus.com/inward/record.url?scp=85061343038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061343038&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2019.01.032
DO - 10.1016/j.atherosclerosis.2019.01.032
M3 - Article
C2 - 30769272
AN - SCOPUS:85061343038
SN - 0021-9150
VL - 283
SP - 1
EP - 6
JO - Atherosclerosis
JF - Atherosclerosis
ER -